Insurance companies must now approve your doctor's drug choice—or explain why in 72 hours

What it does

This bill requires health insurance plans to create a clear, fast process for patients and doctors to request exceptions to 'step therapy' protocols—rules that force patients to try cheaper drugs first before the plan will cover the medication their doctor prescribed. If a patient meets one of six defined circumstances (prior drugs failed, delay would cause serious harm, the required drug causes adverse reactions, the patient is stable on their current drug, or other circumstances the Secretary determines), the plan must cover the requested drug within 72 hours (or 24 hours in emergencies), and that coverage must last at least one year. Plans must report annually to the Department of Labor on how many exceptions they grant or deny.

Why we flagged it

The bill's core mechanism is a procedural mandate requiring insurers to establish transparent exception processes for step-therapy denials, with defined approval criteria and strict timelines. This is fundamentally a patient-protection measure that constrains insurer discretion in drug coverage decisions.

What the text implies

• Pharmacy Benefit Managers (PBMs) will face increased administrative burden and potential revenue loss if step-therapy protocols are overridden more frequently, which may shift costs to plan sponsors or be passed to patients through higher premiums.
• The 'other circumstances' clause in subsection (b)(6) delegates significant authority to the Secretary of Labor to expand exception grounds beyond the six enumerated categories, creating potential for regulatory expansion without further congressional action.
• Annual reporting requirements create a new transparency mechanism that may expose patterns of insurer denials, potentially fueling future legislative pressure for broader coverage mandates or PBM regulation.
• Plans may respond by narrowing step-therapy protocols upfront or raising premiums to offset exception-driven costs, which could indirectly harm patients by reducing plan affordability or choice.
• The one-year minimum coverage duration for approved exceptions may incentivize insurers to deny exceptions more aggressively upfront, knowing that approval locks in coverage for 12 months.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary patients and their doctors gain a transparent, enforceable right to challenge insurance denials of prescribed medications, with strict timelines and defined approval criteria. This reduces delays in accessing medically necessary drugs and shifts power from insurers' cost-containment algorithms back toward clinical judgment, directly benefiting patients with chronic or serious conditions.

Who stands to gain

• pharmaceutical manufacturers (increased drug utilization if step-therapy barriers are lowered)
• patients with chronic conditions requiring non-preferred medications

Named in the bill

Employee Retirement Income Security Act of 1974 (ERISA), Department of Labor (Secretary of Labor), group health plans, health insurance issuers, pharmacy benefit managers (PBMs), third-party administrators, prescribers, participants and beneficiaries

Where it stands

52 cosponsors: 37 Democrats, 14 Republicans, 1 Independents.

• Sep 18, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Sep 18, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

30 lobbying clients named this bill on 37 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $17,284,779 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Lisa Murkowski, the sponsor, reported $364,800 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• Pfizer Inc. — $1,720,000 on 1 filing
• Astrazeneca Pharmaceuticals Lp — $1,680,000 on 1 filing
• Blue Cross and Blue Shield Association — $1,440,000 on 1 filing
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.